Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

103.99 -0.58 (-0.55%)

Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

53 54 Next >

$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today ↗

March 08, 2024

Via Benzinga

Are These 5 Undervalued Stocks Ready to Break Out?

March 08, 2024

Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.

Via MarketBeat

Is Abbott Laboratories a Top Dividend Growth Stock to Buy Now? ↗

March 07, 2024

Abbott Laboratories has been growing its dividend at a blistering pace. Is its stock a buy?

Via The Motley Fool

FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's ↗

March 06, 2024

FDA greenlights DexCom's Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant...

Via Benzinga

3 Dividend Aristocrats With the Largest 10-Year Dividend Growth Rates ↗

March 06, 2024

These three dividend stocks have proved themselves to be among the best Dividend Aristocrats to buy for high-growth returns.

Via InvestorPlace

Exploring ABBOTT LABORATORIES (NYSE:ABT)s quality characteristics. ↗

March 05, 2024

Why the quality investor may take a look at ABBOTT LABORATORIES (NYSE:ABT).

Via Chartmill

$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today ↗

March 01, 2024

Via Benzinga

Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win ↗

March 06, 2024

The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it.

Via Investor's Business Daily

Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite ↗

March 03, 2024

There is a world of opportunities ahead for this healthcare giant.

Via The Motley Fool

Nearing Retirement? These Stocks Are as Cautious as They Come ↗

February 28, 2024

Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further.

Via The Motley Fool

3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade ↗

February 27, 2024

These stocks don't offer the highest yields, but their payouts are growing fast.

Via The Motley Fool

3 Blue-Chip Stocks to Buy to Bolster Your Portfolio ↗

February 26, 2024

Delve into three undervalued blue-chip stocks to buy driving growth in consumer staples, pharmaceuticals, and healthcare.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 26, 2024

Via Benzinga

Could Abbott Laboratories Stock Help You Become a Millionaire? ↗

February 26, 2024

Abbott's earnings have soared over the past decade.

Via The Motley Fool

Abbott Laboratories (NYSE: ABT) Records 52-Week High Friday Morning

February 23, 2024

Via Investor Brand Network

Looking for Growth? 7 Hot Trends That Have Been Flying Under Investors’ Radar. ↗

February 26, 2024

Discover 7 under-the-radar stock trends set to make waves in the stock market. Find out why savvy investors are tuning in.

Via InvestorPlace

Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment ↗

February 23, 2024

Via Benzinga

Recession-Proof Riches: 7 Stocks to Buy for Bulletproof Portfolio Growth ↗

February 23, 2024

Explore recession-proof stocks thriving in Energy, Health Care, Industrials, and more, offering stability and growth amid economic turmoil.

Via InvestorPlace

Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade ↗

February 21, 2024

In a welcome move, Abbott Laboratories stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday.

Via Investor's Business Daily

Peering Into Abbott Laboratories's Recent Short Interest ↗

February 20, 2024

Via Benzinga

3 Cash Cows to Boost Your Confidence During the February Chill ↗

February 18, 2024

The market can be a tricky place. Bet on these cash cow stocks to help restore confidence and extract steady returns.

Via InvestorPlace

This Is What Whales Are Betting On Abbott Laboratories ↗

February 08, 2024

Via Benzinga

The Smartest Dividend Stocks to Buy With $400 Right Now ↗

February 18, 2024

These stocks reward you during any market environment.

Via The Motley Fool

Cardiology's Quantum Leap: FDA's Advisory Panel Gives Thumbs Up To Abbott's Minimally Invasive Heart Valve Repair Device ↗

February 14, 2024

FDA panel confirms support (13-1) for Abbott Laboratories' TriClip TEER system in treating tricuspid regurgitation. Approval decision expected from FDA in 2024.

Via Benzinga

FDA Advisors Set To Discuss Abbott's TriClip For Heart Valve Disorder As Questions On Pivotal Trial Loom ↗

February 12, 2024

FDA to review Abbott's TriClip G4 System for severe tricuspid regurgitation. Circulatory System Devices Panel meeting and insights from the briefing document.

Via Benzinga

Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How. ↗

February 11, 2024

Abbott Labs has an impressive portfolio of nutrition drinks, and its latest addition could help it profit from a new market: people taking prescribed weight loss drugs.

Via The Motley Fool

3 Groundbreaking Healthcare Stocks to Buy for Robust Gains ↗

February 11, 2024

Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector.

Via InvestorPlace

These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys? ↗

February 09, 2024

There's room for multiple winners in the fast-growing weight-loss market.

Via The Motley Fool

Abbott Laboratories Stock Getting Closer To Key Technical Benchmark ↗

February 07, 2024

Abbott Laboratories shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

7 Tremendous Dividend Stocks With Double-Digit 5-Year Growth Rates ↗

February 07, 2024

When it comes to buying dividend stocks, investors should seek out companies that consistently and repliably grow their payout over time.

Via InvestorPlace

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.